US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Teva Pharmaceutical Industries Ltd
< Previous
1
2
3
4
Next >
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
November 19, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
November 07, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
November 05, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis
November 03, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
October 31, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
October 20, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
October 10, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Releases Q3 2025 Aide Memoire
September 25, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
September 25, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
September 20, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
September 20, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
September 16, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
September 09, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
September 02, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
August 28, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
August 06, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
July 30, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Releases Q2 2025 Aide Memoire
June 26, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
June 25, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
June 16, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
June 03, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
June 03, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
May 30, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with
May 30, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
May 29, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
May 22, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
May 20, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
< Previous
1
2
3
4
Next >
